Acta Medica (Jan 2010)

The Counter-Regulation of Atherogenesis: a Role for Interleukin-33

  • Pavel Kuneš,
  • Zdeňka Holubcová,
  • Martina Koláčková,
  • Jan Krejsek

DOI
https://doi.org/10.14712/18059694.2016.71
Journal volume & issue
Vol. 53, no. 3
pp. 125 – 129

Abstract

Read online

The recently recognized cytokine interleukin-33 and its receptor ST2 play a favorable role during atherogenesis by inducing a Th1→Th2 shift of the immune response. IL-33 also protects the failing human heart from harmful biomechanical forces which lead to cardiomyocyte hypertrophy and exaggerated interstitial fibrosis. IL-33 inevitably displays side effects common to other Th2 cytokines, the most grave of which is a predisposition to allergic reactions. IL-33 is a nuclear transcription factor of endothelial cells. As such, it is abundant in nonproliferating vessels. Its down-regulation is required for angiogenesis, which may be profitable in wound healing or deleterious in tumor growth.

Keywords